Jun 4, 2026, 15:53
Rituximab and Eculizumab in Refractory Antiphospholipid Syndrome – APS Foundation of America
APS Foundation of America shared a post on LinkedIn:
“Rituximab and Eculizumab Show Benefit in Refractory Antiphospholipid Syndrome
Key Point: Across biologic therapies for antiphospholipid syndrome APS), rituximab and eculizumab had the most robust data, while belimumab and daratumumab were promising but supported by very limited early evidence.
‘Ultimately, personalized strategies integrating clinical phenotype, serology, and pathogenic mechanisms may offer the best approach for optimizing care in patients with refractory or complex APS.'”
Read More.”
Stay updated on all scientific advances in the field of fertility with Fertility News.
-
Nov 2, 2026, 17:08Elena Milner: The 2nd Class of the School of Embryology Is Already in Full Swing
-
Nov 2, 2026, 17:05November Is National Diabetes Month – PCOS Awareness Association
-
Nov 2, 2026, 17:04Thanos Papathanasiou: Are We Preparing Patients for the IVF Cycle, or for the IVF Journey?
-
Nov 2, 2026, 17:02Anna Morales: Why Is It So Hard to Build in Women’s Health?
-
Nov 2, 2026, 16:59Rickard Ericsson: Honored to Take on the Role of Interim CEO of the Vitrolife Group
-
Nov 2, 2026, 16:56Mohammed Nasur: 1 Small Simulation, A Bigger Purpose
-
Nov 2, 2026, 16:54Carlos Guerrero: Presenting Our Latest Research on AI and Embryo Assessment at ASRM 2026
-
Nov 2, 2026, 16:52Sarah Lewen: My 1st ASRM Is Officially Complete
-
Nov 2, 2026, 16:49Jemma Garratt: Taking on the Role of Kind IVF and Data Science Manager at London Women’s Clinic